Royal Bank Of Canada Cognition Therapeutics Inc Transaction History

Royal Bank Of Canada

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.66 - $2.62 $554 - $875	334 Added 8350.0%	338 $0
Q1 2024 Nov 05, 2024	SELL	$1.78 - $2.53 $594 - $845	-334 Reduced 98.82%	4 $0
Q1 2024 May 15, 2024	SELL	$1.78 - $2.53 $347 - $493	-195 Reduced 97.99%	4 $0
Q4 2023 Feb 14, 2024	BUY	$0.96 - $2.42 $168 - $425	176 Added 765.22%	199 $0
Q3 2023 Nov 14, 2023	SELL	$1.25 - $1.9 $288 - $438	-231 Reduced 90.94%	23 $0
Q2 2023 Aug 14, 2023	BUY	$1.56 - $3.38 $396 - $858	254 New	254 $0
Q4 2022 Feb 14, 2023	BUY	$1.17 - $3.51 $336 - $1,010	288 Added 257.14%	400 $0
Q3 2022 Nov 14, 2022	BUY	$1.63 - $3.6 $182 - $403	112 New	112 $0
Q1 2022 May 16, 2022	SELL	$2.41 - $6.9 $241 - $690	-100 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$5.1 - $12.98 $509 - $1,298	100 New	100 $1,000

6.58M

Ticker CGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,710,700
Market Cap $13.2M
Description
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical tr...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.